Terms: = Head and neck cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Clinical Outcome
5 results:
1. Prognostic Significance of the Microenvironment in Human Papillomavirus Oropharyngeal Carcinoma: A Systematic Review.
Baudouin R; Hans S; Lisan Q; Morin B; Adimi Y; Martin J; Lechien JR; Tartour E; Badoual C
Laryngoscope; 2024 Apr; 134(4):1507-1516. PubMed ID: 37642393
[TBL] [Abstract] [Full Text] [Related]
2. The clinical outcome in Patients Treated With a Newly Designed SEMS in Cervical Esophageal Strictures and Fistulas.
Poincloux L; Sautel C; Rouquette O; Pereira B; Goutte M; Bommelaer G; Dapoigny M; Abergel A
J Clin Gastroenterol; 2016; 50(5):379-87. PubMed ID: 26927492
[TBL] [Abstract] [Full Text] [Related]
3. The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma.
Davison JM; Yee M; Krill-Burger JM; Lyons-Weiler MA; Kelly LA; Sciulli CM; Nason KS; Luketich JD; Michalopoulos GK; LaFramboise WA
PLoS One; 2014; 9(1):e79079. PubMed ID: 24454681
[TBL] [Abstract] [Full Text] [Related]
4. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract] [Full Text] [Related]
5. cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications.
Nijdam W; Levendag P; Noever I; Groot CU; Agthoven Mv
Radiother Oncol; 2005 Oct; 77(1):65-72. PubMed ID: 16213619
[TBL] [Abstract] [Full Text] [Related]
